• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

    5/16/25 8:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $WINT alert in real time by email

    WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates.

    "The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a revenue generating company by seeking to identify and acquire revenue-generating FDA-approved assets while advancing our cardiology and oncology pipeline," said Jed Latkin, Chief Executive Officer of Windtree. Mr. Latkin continued, "We believe that this strategy has the potential to transform Windtree into both a commercial and development stage company that generates revenue, helps patients and enhances our attractiveness to shareholders. The Company entered into an initial strategic transaction for a right to buy a revenue-generating multifamily residential property. Leveraging off our firm partnership in China we are helping a rapidly growing biopharmaceutical company lower their costs of production by almost 65%. We anticipate the partnership should start generating revenues by the end of 2026. We continue to develop our pipeline, including the ongoing enrollment of subjects in the istaroxime cardiogenic shock SCAI Stage C study. We plan an interim analysis of the first 20 subjects in Q3 2025. This study, when completed, is intended to advance the program to Phase 3 in cardiogenic shock, a condition with significant mortality and morbidity. Drug innovation in cardiogenic shock is desired, and we believe that istaroxime has the potential to provide unique benefits over other currently available drugs. We look forward to continued communication with our shareholders on our progress on all our initiatives."

    Key Business Updates

    • Announced a late-breaking clinical science abstract presentation on istaroxime at the Technology and Heart Failure Therapeutics Conference.
    • Entered into a license and supply agreement to become the sourcing partner for Evofem Biosciences, Inc. for PHEXXI® (lactic acid, citric acid and potassium bitartrate), a first-in-class hormone-free, on-demand prescription contraceptive vaginal gel that women control. The Company intends to leverage its manufacturing contacts to reduce pharmaceutical product cost of goods for PHEXXI.
    • Announced a strategic transaction to drive revenue generation in support of our ongoing therapeutic pipeline development. The initial transaction provides the right to buy the target asset which may provide consistent revenue to the Company while it continues to develop its biotech pipeline drug candidates. The transaction is an assignment and conditional assumption agreement with a seasoned real estate investment group pursuant to which the Company has gained the rights to purchase a 436 unit, multifamily residential property in Houston, Texas.
    • Closed on a private placement transaction in April 2025 and May 2025 for aggregate gross proceeds of approximately $2.6 million related to the issuance of Series D convertible preferred stock.
    • Regained Nasdaq compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing. The Company will be subject to a mandatory panel monitor until March 20, 2026.
    • Continued expansion of our patent estate for istaroxime with the granting of a notice of allowance in acute heart failure by the United States Patent and Trademark Office as well as a patent filing in India. For the preclinical oncology aPKCi inhibitor, a patent was issued for Japan.   

    Select First Quarter 2025 Financial Results

    For the fiscal quarter ended March 31, 2025, the Company reported an operating loss of $4.1 million compared to an operating loss of $4.4 million in the first quarter of 2024.

    Research and development expenses were $2.3 million for the first quarter of 2025, compared to $2.3 million for the first quarter of 2024. Research and development expenses primarily relate to the continued development of istaroxime for the treatment of early cardiogenic shock, including costs related to the SEISMiC C trial during the first quarter of 2025 and costs related to the SEISMiC Extension trial during the first quarter of 2024.

    General and administrative expenses for the first quarter of 2025 were $1.8 million, compared to $2.1 million for the first quarter of 2024. The $0.3 million decrease in general and administrative expenses is due to a decrease of $0.2 million in professional fees, primarily related to reduced legal fees and a decrease of $0.1 million in non-cash stock-based compensation expense.

    The Company reported a net loss attributable to common stockholders of $5.0 million ($4.63 per basic share) on 1,088,564 weighted-average common shares outstanding for the quarter ended March 31, 2025, compared to net income of $10.2 million ($1,099.37 per basic share) on 9,295 weighted average common shares outstanding for the comparable period in 2024.

    As of March 31, 2025, the Company reported cash and cash equivalents of $1.2 million and current liabilities of $6.5 million. We believe that we have sufficient resources available to fund our business operations through May 2025. 

    Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which was filed with the Securities and Exchange Commission on May 15, 2025, and includes detailed discussions about the Company's business plans and operations, financial condition, and results of operations.

    About Windtree Therapeutics, Inc.

    Windtree Therapeutics, Inc. is a biotechnology company focused on becoming a revenue-generating company and advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the Company's ability to maintain compliance with the continued listing requirements of Nasdaq; the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Israel and Gaza, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

    Contact Information:

    Eric Curtis

    [email protected]



    WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES

    Consolidated Balance Sheets

    (in thousands, except share and per share data)
      March 31, 2025  December 31, 2024 
      (Unaudited)     
    ASSETS        
    Current assets:        
    Cash and cash equivalents $1,173  $1,779 
    Prepaid expenses and other current assets  421   795 
    Total current assets  1,594   2,574 
             
    Property and equipment, net  94   111 
    Restricted cash  9   9 
    Operating lease right-of-use assets  939   1,051 
    Intangible assets  24,130   24,130 
    Total assets $26,766  $27,875 
             
    LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' EQUITY        
    Current liabilities:        
    Accounts payable $3,110  $1,879 
    Accrued expenses  1,785   1,706 
    Operating lease liabilities - current portion  519   508 
    ELOC commitment note payable  -   328 
    Derivative liability - ELOC commitment note  -   299 
    Senior secured notes payable  374   - 
    Common stock warrant liability  162   305 
    Loans payable  167   333 
    Other current liabilities  359   359 
    Total current liabilities  6,476   5,717 
             
    Operating lease liabilities - non-current portion  519   653 
    Other liabilities  3,800   3,800 
    Deferred tax liabilities  4,643   4,528 
    Total liabilities  15,438   14,698 
             
    Mezzanine equity:        
    Series C redeemable preferred stock, $0.001 par value; 18,820 shares authorized; 2,833 and 11,757 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively  1,038   3,181 
    Series B redeemable preferred stock, $0.001 par value; 5,500 shares authorized; 0 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively  -   - 
    Total mezzanine equity  1,038   3,181 
             
    Stockholders' equity:        
    Preferred stock, $0.001 par value; 4,975,680 shares authorized; 0 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively  -   - 
    Common stock, $0.001 par value; 120,000,000 shares authorized; 3,555,954 and 256,397 shares issued and 3,555,953 and 256,396 shares outstanding at March 31, 2025 and December 31, 2024, respectively  4   - 
    Additional paid-in capital  863,995   859,660 
    Accumulated deficit  (850,655)  (846,610)
    Treasury stock (at cost); 1 share  (3,054)  (3,054)
    Total stockholders' equity  10,290   9,996 
    Total liabilities, mezzanine equity & stockholders' equity $26,766  $27,875 



    WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES

    Consolidated Statements of Operations

    (in thousands, except share and per share data)
      Three Months Ended 
      March 31, 
      2025  2024 
             
    Expenses:        
    Research and development $2,270  $2,253 
    General and administrative  1,820   2,152 
    Total operating expenses  4,090   4,405 
    Operating loss  (4,090)  (4,405)
             
    Other income (expense):        
    (Loss) gain on debt extinguishment, net  (22)  14,520 
    Change in fair value of common stock warrant liability  134   - 
    Interest income  7   30 
    Interest expense  (20)  (13)
    Other (expense) income, net  (54)  201 
    Total other income, net  45   14,738 
             
    (Loss) income before income taxes  (4,045)  10,333 
    Income tax expense  -   (114)
    Net (loss) income $(4,045) $10,219 
    Dividends on Series C preferred stock  (998)  - 
    Net (loss) income attributable to common stockholders $(5,043) $10,219 
             
    Net (loss) income per share attributable to common stockholders        
    Basic and diluted $(4.63) $1,099.37 
             
    Weighted average number of common shares outstanding        
    Basic and diluted  1,088,564   9,295 


    Primary Logo

    Get the next $WINT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Kelly Leanne

      3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      1/14/25 4:17:38 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      10/9/24 7:46:52 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Pelletier Saundra L

      3 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      8/14/24 4:24:25 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      10/9/24 7:46:52 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fraser Craig bought $2,550 worth of shares (2,500 units at $1.02), increasing direct ownership by 5% to 57,877 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      9/28/23 7:24:59 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fraser Craig bought $2,250 worth of shares (2,500 units at $0.90), increasing direct ownership by 5% to 55,377 units (SEC Form 4)

      4 - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Issuer)

      9/27/23 7:34:59 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    SEC Filings

    See more
    • Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      7/3/25 2:26:36 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits

      8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      6/27/25 5:27:55 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Filer)

      6/20/25 5:20:24 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure

      1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039 WARRINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the United States Patent and Trademark Office has issued an istaroxime patent for the United States - application number 18/150,870 directed to "ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE T

      7/2/25 9:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis

      The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously reported two positive early cardiogenic shock Phase 2 studies in SCAI Stage B patients The SEISMiC C interim analysis will provide a preliminary assessment of istaroxime safety in treating more severe cardiogenic shock patients who may be receiving standard of care with inotropes and vasopressors SCAI Stage C is a sicker patient population than early cardiogenic shock and has high mortality despite currently used drug treatments WARRINGTON, Pa., June 30, 2025 (GLOBE NEWSWIRE) --

      6/30/25 9:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel

      Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer underway with validation batch manufacturing expected to begin in 2026 Evofem and Windtree exploring other partnerships WARRINGTON, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NASDAQ:WINT) today announced that it has contracted with a pharmaceutical manufacturer in China to produce Evofem's hormone-free contraceptive product, PHEXXI® (lactic acid, citric acid and potassium bitartrate), at a cost that is significantly bel

      6/26/25 4:05:00 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Leadership Updates

    Live Leadership Updates

    See more
    • Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

      Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

      6/9/25 8:15:00 AM ET
      $ADTX
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

      WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the appointment of Leanne Kelly to its board of directors ("Board"). Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee. Ms. Kelly has served as GRI Bio's Chief Financial Officer since April 2023. She brings over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors w

      1/13/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Announces Leadership Transition Plan With Industry Veterans

      WARRINGTON, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser plans to retire from his role as Chief Executive Officer, effective December 1, 2024, after nearly nine years of distinguished service to the Company. Mr. Fraser will remain on the Board of Directors of the Company as Chairman. The Company's Board has appointed Jed Latkin, a current director of the Company, to replace Mr. Fraser as CEO and Mr. Latkin will also remain a member of the Board. Mr. Fraser has ser

      11/14/24 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Windtree Therapeutics with a new price target

      Oppenheimer initiated coverage of Windtree Therapeutics with a rating of Outperform and set a new price target of $8.00

      6/4/21 6:09:49 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Financials

    Live finance-specific insights

    See more
    • Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the first quarter ended March 31, 2025 and provided key business updates. "The first quarter of 2025 was marked with significant progress. We announced our new corporate strategy to become a revenue generating company by seeking to identify and acquire revenue-generating FDA-approved assets while advancing our cardiology and oncology pipeline," said Jed Latkin, Chief Executive

      5/16/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

      WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. "The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy of the Company," said Jed Latkin, CEO of Windtree. "Cardiogenic shock is a critical condition with high morbidity and mortality where clinician

      4/15/25 8:00:00 AM ET
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Evofem Reports Fourth Consecutive Year of Net Sales Growth

      -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

      3/24/25 8:30:00 AM ET
      $ADTX
      $EVFM
      $WINT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $WINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

      SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 7:15:44 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Windtree Therapeutics Inc.

      SC 13G - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 3:40:27 PM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

      SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

      11/14/24 8:53:39 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care